Allakos Stock Forecast, Price & News

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last twelve months. There are currently 1 sell rating, 7 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Allakos stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALLK, but not buy additional shares or sell existing shares.
View analyst ratings for Allakos or view top-rated stocks.

10 Wall Street analysts have issued 1 year target prices for Allakos' shares. Their ALLK stock forecasts range from $13.00 to $155.00. On average, they anticipate Allakos' share price to reach $68.42 in the next twelve months. This suggests a possible upside of 1,960.9% from the stock's current price.
View analysts' price targets for Allakos or view top-rated stocks among Wall Street analysts.

Allakos' stock was trading at $9.79 at the start of the year. Since then, ALLK stock has decreased by 66.1% and is now trading at $3.32.
View the best growth stocks for 2022 here.

Allakos is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Allakos.

Allakos Inc. (NASDAQ:ALLK) released its quarterly earnings data on Friday, May, 6th. The company reported ($3.60) earnings per share for the quarter, missing the consensus estimate of ($1.71) by $1.89.
View Allakos' earnings history.

Some companies that are related to Allakos include Kiniksa Pharmaceuticals (KNSA), MorphoSys (MOR), CinCor Pharma (CINC), Avidity Biosciences (RNA), Catalyst Pharmaceuticals (CPRX), Erasca (ERAS), Northwest Biotherapeutics (NWBO), Theravance Biopharma (TBPH), Ventyx Biosciences (VTYX), Emisphere Technologies (EMIS), Keros Therapeutics (KROS), Nuvalent (NUVL), Zealand Pharma A/S (ZEAL), Organogenesis (ORGO) and POINT Biopharma Global (PNT).
View all of ALLK's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Allakos investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), Pfizer (PFE), Agios Pharmaceuticals (AGIO), Biohaven Pharmaceutical (BHVN), bluebird bio (BLUE), Eastman Chemical (EMN), Heron Therapeutics (HRTX), TG Therapeutics (TGTX) and Arbutus Biopharma (ABUS).

(ALLK) raised $96 million in an IPO on Thursday, July 19th 2018. The company issued 6,000,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and William Blair was co-manager.

Allakos trades on the NASDAQ under the ticker symbol "ALLK."

Allakos' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (5.32%), Vanguard Group Inc. (4.84%), Goldman Sachs Group Inc. (1.84%), State Street Corp (1.43%), PDT Partners LLC (1.21%) and Clearline Capital LP (0.98%). Company insiders that own Allakos stock include Adam Tomasi, Daniel Janney, Guy P Nohra, Henrik S Md Rasmussen, John P Mckearn, Paul Edward Walker, Peter A Hudson, Robert Alexander, Robert J More and Steven P James.
View institutional ownership trends for Allakos.

ALLK stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., State Street Corp, Simplex Trading LLC, Group One Trading L.P., Bank of America Corp DE, Citigroup Inc., RBF Capital LLC, and Cutler Group LP. Company insiders that have sold Allakos company stock in the last two years include Adam Tomasi, Daniel Janney, Henrik S Md Rasmussen, Paul Edward Walker, Peter A Hudson, Robert Alexander, Robert J More, and Steven P James.
View insider buying and selling activity for Allakos or view top insider-selling stocks.

ALLK stock was bought by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., PDT Partners LLC, Clearline Capital LP, JPMorgan Chase & Co., Acadian Asset Management LLC, Healthcare of Ontario Pension Plan Trust Fund, BlackRock Inc., and Renaissance Technologies LLC.
View insider buying and selling activity for Allakos or or view top insider-buying stocks.

Shares of ALLK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALLK stock can currently be purchased for approximately $3.32.

Allakos (NASDAQ:ALLK) has a market capitalization of $181.86 million. The company earns $-269.86 million in net income (profit) each year or ($7.56) on an earnings per share basis.

Allakos employs 192 workers across the globe.

Allakos' mailing address is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. The official website for Allakos is www.allakos.com. The company can be reached via phone at (650) 597-5002 or via email at [email protected].